Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Russell Flannery - Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Forbes

David Ricks, chief executive officer of Eli Lilly & Co., speaks during the China Development Forum in Beijing in March this year. Photographer: Qilai Shen/Bloomberg © 2026 Bloomberg Finance LP In the latest China pharmaceutical industry…

247wallst.com - Trey Thoelcke - 3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
24/7 Wall St

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets. Patent cliffs approach, GLP-1 franchises…

benzinga.com - Tanya Rawat - ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - ARS Pharma
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - ARS Pharma
Benzinga

ARS Pharmaceuticals, Inc. (NASDAQ:) shares fell in after-hours trading on Wednesday after the company provided commercial and financial updates, including no new formulary additions for Neffy in the July 2026 coverage cycle. SPRY closed Wednesday's…

swissinfo.ch - Aylin Elçi - Swiss healthcare costs rise faster than patients can keep up
Swiss healthcare costs rise faster than patients can keep up
www.swissinfo.ch

Switzerland's mandatory health insurance premiums reached CHF423 ($470) monthly in 2024 – 7% of disposable income, up from 4% in 2004. Parliament approved 16 cost-containment measures in March 2025, but a referendum capping premiums at 10%…

bloomberg.com - Sonja Wind - Merck KGaA Agrees on $11.3 Billion Purchase of Bio-Techne
Merck KGaA Agrees on $11.3 Billion Purchase of Bio-Techne
Bloomberg

Merck KGaA agreed to buy Bio-Techne Corporation for $11.3 billion to bolster its life-science business, marking the German pharma and technology group's biggest acquisition in more than a decade. Merck agreed to pay $73 per share in cash for the US…

bloomberg.com - Michelle Fay Cortez - Inside the Lilly CEO's Plan to Build on Its $1 Trillion Weight-Loss Empire
Inside the Lilly CEO's Plan to Build on Its $1 Trillion Weight-Loss Empire
Bloomberg

This article is for subscribers only. Welcome back to Bloomberg's Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the future of medicine. Sign up now if you're not already on the list. Lilly's…

cnbc.com - Reuters - Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
CNBC

Arne Dedert | Picture Alliance | Getty Images German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, expanding its presence in the life sciences market. Shares of Bio-Techne rose 22% in…

seekingalpha.com - Mare Evidence Lab - Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY)
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY)
Seeking Alpha

Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing…

seekingalpha.com - ALLKA Research - Is GSK Quietly Becoming An Oncology Powerhouse (NYSE:GSK)
Is GSK Quietly Becoming An Oncology Powerhouse (NYSE:GSK)
Seeking Alpha

GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and…

lewrockwell.com - Paul Craig Roberts - America on the Ropes
America on the Ropes
LewRockwell

Dear Readers, our politicians don't rile us up against “foreign enemies,” Russians, Iranians, Chinese, and “Muslim terrorists”–Osama bin Laden in Afghanistan, Saddam Hussein in Iraq, Gadaffi in Libya, Assad in…

dynamitenews.com - Donika Singh - Stock Market Today: Why sensex, nifty opened higher as crude slipped near $70 | Dynamite News
Stock Market Today: Why sensex, nifty opened higher as crude slipped near $70 | Dynamite News
News: Today's News Headlines & Daily Updates from Sports, Movies, Politics, Business | Dynamite News

Post Published By: Donika Singh Updated: 25 June 2026, 9:46 AM IST New Delhi: Indian stock markets opened higher on Thursday as crude oil prices eased towards the $70-per-barrel mark, with tankers resuming their exit from the Strait of Hormuz…

crunchbase.com - Joanna Glasner - Cursor Deal Puts US On Track For Record Startup M&A Year
Cursor Deal Puts US On Track For Record Startup M&A Year
Crunchbase

When someone spends $60 billion to buy a startup, M&A spending suddenly starts looking pretty robust. Those were the unsurprising findings of a Crunchbase analysis of U.S. startup acquisition outlays in 2026. So far this year, acquirers have spent…

fool.com - Thomas Niel - An Analyst Just Declared Eli Lilly the 'Clear Winner' of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
An Analyst Just Declared Eli Lilly the 'Clear Winner' of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
The Motley Fool

In the eyes of Wall Street, Eli Lilly (LLY +2.19%) continues to cement its lead over the competition in the field of weight-loss and diabetes drugs. After revealing a pair of positive developments coinciding with the American Diabetes Association's…

rediff.com - Text Feed - SETL Expands Into AI Datacenter Engineering With Strategic GScale Energy Acquisition
SETL Expands Into AI Datacenter Engineering With Strategic GScale Energy Acquisition
Rediff.com

Hyderabad-based SETL has strategically acquired a majority stake in GScale Energy, committing Rs 500 crore to expand its precision engineering expertise into the burgeoning AI Datacenter infrastructure market, powering India's digital future. SETL…

seekingalpha.com - Petri Dish Reports - Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Seeking Alpha

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces…

Receive a Daily briefing on Pharma Industry News

Get Started